Pharmafile Logo

5 takeaways from Reuters’ Pharma USA 2026 – and what they mean for you

April 15, 2026 |  

Pharma USA is North America’s largest cross-functional pharma event and Inizio was there to offer insights on patient engagement, accelerated product launches, and Intelligent Commercialization™. Now we’re back in the office, it’s time to share our thoughts on some of the key themes discussed in Philadelphia.

- PMLiVE

More than a dozen colleagues from Inizio IgniteInizio Engage, and Inizio Evoke attended Pharma USA 2026 in mid-March. While we were there, we ran a workshop on designing insight-driven patient support, and hosted a live session on the practical strategies pharma teams can employ to drive focus, alignment, and smarter product launch execution.

These types of events are an excellent way to take the pulse of pharma and, with more than 170 speakers and 20 interactive sessions, Pharma USA was once again a hive of interesting ideas and hot topics.

1. AI is everywhere – but the real differentiator is the quality of the data behind it.

It’s no surprise that conversations about AI were happening everywhere at Pharma USA, but one of the more interesting takes wasn’t about the amazing things the technology can do, but how quality data is fundamental to its successful implementation.

What became clear in conversations across the event is that while many organizations are investing heavily in AI, those seeing real impact are the ones grounding it in well-structured, proprietary data and embedding it into real decision-making workflows.

In a landscape where teams are already navigating increasing complexity, more stakeholders, and compressed timelines, simply adding more data or tools does not guarantee better outcomes. The real question is whether those inputs are improving decision quality and enabling action at speed.

Read the full article here. 

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Video: Immuno-oncology therapies

Immuno-oncology therapies which harness the body’s own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment. However, these therapies come with a very high...

Event: EULAR Annual European Congress of Rheumatology 2016

We are delighted to be attending the EULAR Annual European Congress of Rheumatology in June. Representing Research Partnership is Business Development Manager, Fara Mboge. He will be on hand to...

Forever Angels achievements and development plan for 2016

Research Partnership is proud to support Forever Angels in their mission of caring for and improving the lives of orphans and abandoned infants in Tanzania

The Opportunity for Women’s Health in Emerging Markets

Published in eyeforpharma April 2016 by Rachel Howard

Video: Storytelling in healthcare market research

Within the pharmaceutical industry, there is an increasing need for market research teams to share the insights with their key internal stakeholders, from marketing and brand managers to sales reps...

Promotions and new appointments across our global offices

Research Partnership is delighted to announce promotions and new starters in the UK and further appointments in the US and Singapore offices

Free Thinking: Are biosimilars the answer to the rising cost of RA treatment?

In a past Free Thinking paper, we looked at the opportunity and challenges for biosimilar mAbs entering the rheumatoid arthritis market. A few years later and according to our Therapy...

Webcast: Understanding the Chronic Disease Patient Journey in Emerging Markets

In emerging markets where primary care systems do not exist, the patient is the only constant in the journey

PEGASUS JOINS ASHFIELD HEALTHCARE COMMUNICATIONS

Pegasus, one of the most successful integrated healthcare communications consultancies in the UK, has today announced it has been acquired by UDG Healthcare plc, a FTSE 250 listed international provider...

Living with Crohn’s Report

Are you looking for a deeper understanding of the emotional needs, behaviours and treatment programmes of patients living with Crohn’s Disease?